Minnesota Policy on Pharmacist-Prescribed Contraceptives: Benefits, Limitations, and Opportunities for Improvement.
Access to Care
Birth Control
Community Pharmacy
Contraception
Pharmacist Prescribing
Pharmacy Legislation
Pharmacy Policy
Pharmacy Services
Public Health Services
Journal
Innovations in pharmacy
ISSN: 2155-0417
Titre abrégé: Innov Pharm
Pays: United States
ID NLM: 101574764
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
In August 2020, pharmacists were authorized to prescribe contraceptives in Minnesota outside of a collaborative practice agreement. To practice under this new authorization, pharmacists must complete formal contraceptive prescribing training and follow guidelines which include restrictions on patient's age and appropriate screening and assessment requirements. Allowing pharmacists to prescribe contraceptives has the potential to extend contraceptive access, decrease overall health care costs, and improve outcomes. However, barriers to the expansion of contraceptive prescribing by pharmacists may prevent widespread adoption of this practice in Minnesota. A key concern among pharmacists is a lack of reimbursement for providing this service. Other states adopting contraceptive prescribing by pharmacists which have not paid for this service have reported limited implementation and discontinuation of this service. To improve contraceptive access to Minnesotans, policymakers should consider expanding provider status to pharmacists and providing reimbursement to pharmacists for contraceptive services.
Identifiants
pubmed: 35601594
doi: 10.24926/iip.v12i3.3923
pmc: PMC9119991
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© Individual authors.
Références
J Am Pharm Assoc (2003). 2016 Sep-Oct;56(5):521-6
pubmed: 27594105
Contraception. 2019 Apr;99(4):239-243
pubmed: 30562478
Pharmacy (Basel). 2020 Aug 17;8(3):
pubmed: 32824468
J Am Pharm Assoc (2003). 2020 Sep - Oct;60(5):e34-e39
pubmed: 32144081
Obstet Gynecol. 2019 Jun;133(6):1231-1237
pubmed: 31135739
J Am Pharm Assoc (2003). 2020 Nov - Dec;60(6):963-968.e2
pubmed: 32800456
Obstet Gynecol. 2016 Jul;128(1):168-170
pubmed: 27275808
Contraception. 2018 Mar;97(3):249-255
pubmed: 29223497
J Pharm Pract. 2019 Feb;32(1):54-61
pubmed: 29096570
Pharmacy (Basel). 2020 Jul 08;8(3):
pubmed: 32650367
Contraception. 2006 Dec;74(6):463-70
pubmed: 17157103
J Am Pharm Assoc (2003). 2018 Nov - Dec;58(6):608-613
pubmed: 30190201
Obstet Gynecol. 2019 Jun;133(6):1238-1246
pubmed: 31135740
Pharmacy (Basel). 2020 Sep 23;8(4):
pubmed: 32977545
Pharmacy (Basel). 2020 Mar 28;8(2):
pubmed: 32231073
Contraception. 2021 Feb;103(2):66-74
pubmed: 33130109
JAMA Netw Open. 2020 May 1;3(5):e205252
pubmed: 32432710
Pharmacy (Basel). 2020 Jun 09;8(2):
pubmed: 32526878
JAMA. 2017 Dec 12;318(22):2253-2254
pubmed: 29234797
J Pharm Pract. 2021 Apr;34(2):230-238
pubmed: 31390938
J Am Pharm Assoc (2003). 2020 Sep - Oct;60(5):e57-e63
pubmed: 32249171
JAMA Netw Open. 2020 Jul 1;3(7):e209132
pubmed: 32667653
J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):212-226
pubmed: 18359734